- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05068011
Differensialmål multiplekset ryggmargsstimulering (DETECT)
Differensiell mål multiplekset ryggmargsstimulering: en multisenter kohortstudie
Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
-
Antwerp, Belgia
- ZNA
-
Bruges, Belgia
- AZ Sint-Jan Brugge-Oostende
-
Bruges, Belgia
- AZ Sint-Lucas Brugge
-
Hasselt, Belgia
- Jessa Ziekenhuis
-
Kortrijk, Belgia
- AZ Groeninge
-
Leuven, Belgia
- UZ Leuven
-
Lier, Belgia
- Heilig Hart Ziekenhuis Lier
-
Liège, Belgia
- Centre Hospitalier Régional (CHR) de la Citadelle
-
Mechelen, Belgia
- AZ Sint-Maarten
-
Roeselare, Belgia
- AZ Delta
-
Sint-Niklaas, Belgia
- Vitaz
-
Turnhout, Belgia
- AZ Turnhout
-
Wilrijk, Belgia
- GZA
-
-
Brussels Capital
-
Jette, Brussels Capital, Belgia, 1090
- Universitair Ziekenhuis Brussel
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.
Beskrivelse
Inclusion Criteria:
- Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
- Age > 18 years
- Patient has been informed of the study procedures and has given written informed consent
- Patient willing to comply with study protocol including attending the study visits
Exclusion Criteria:
- Expected inability of the patient to receive or properly operate the spinal cord stimulation system
- History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
- Active malignancy
- Addiction to drugs, alcohol (>5 units per day) and/or medication
- Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
- Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
- Life expectancy < 1 year
- Local infection or any other skin disorder at site of incision
- Pregnancy
- Other implanted active medical device
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Spinal cord stimulation
Patients will receive differential target multiplexed spinal cord stimulation |
differential target multiplexed stimulation |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall pain intensity with Visual Analogue Scale (VAS)
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Intensitet av ryggsmerter med Visual Analogue Scale (VAS)
Tidsramme: Endringen mellom baseline-screeningen og evalueringen 1 måned etter DTM-stimulering, 6 måneder og 12 måneder
|
Endringen mellom baseline-screeningen og evalueringen 1 måned etter DTM-stimulering, 6 måneder og 12 måneder
|
|
|
Bein smerteintensitet med Visual Analogue Scale (VAS)
Tidsramme: Endringen mellom baseline-screeningen og evalueringen 1 måned etter DTM-stimulering, 6 måneder og 12 måneder
|
Endringen mellom baseline-screeningen og evalueringen 1 måned etter DTM-stimulering, 6 måneder og 12 måneder
|
|
|
Klinisk holistisk responderstatus
Tidsramme: Endringen mellom baseline-screeningen og evalueringen 1 måned etter DTM-stimulering, 6 måneder og 12 måneder
|
Endringen mellom baseline-screeningen og evalueringen 1 måned etter DTM-stimulering, 6 måneder og 12 måneder
|
|
|
Andel vellykkede DTM-forsøk.
Tidsramme: Evaluert etter siste SCS-implantasjon
|
Evaluert etter siste SCS-implantasjon
|
|
|
Batteriforbruk
Tidsramme: Registrering ved 1 måned, 6 måneder og 12 måneder av DTM SCS
|
Registrering ved 1 måned, 6 måneder og 12 måneder av DTM SCS
|
|
|
Utbredelse av tekniske problemer med hensyn til DTM SCS-programmering
Tidsramme: Gjennom hele studietiden
|
Gjennom hele studietiden
|
|
|
DTM SCS-stimuleringsparametere
Tidsramme: Registrering ved 1 måned, 6 måneder og 12 måneder av DTM SCS
|
Registrering ved 1 måned, 6 måneder og 12 måneder av DTM SCS
|
|
|
Pain medication use
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Open question regarding the dosage, frequency and type of pain medication |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Functional disability
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The functional disabilities will be assessed with the Oswestry Disability Index (ODI) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Health related quality of life
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Patient global impression of change
Tidsramme: Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC). |
Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
|
Patients' individual competencies for self-management
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health. |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Work status
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Work status is evaluated with a self-designed questionnaire |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Pain catastrophizing
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Symptoms of central sensitisation.
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Central Sensitization Inventory is used to measure symptoms of central sensitisation |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Anxiety and Depression.
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Healthcare utilisation.
Tidsramme: The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
Postoperative healthcare expenditure will be investigated by self-reporting methods. |
The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
|
Time spent in body postures
Tidsramme: The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
Based on the AdaptiveStim technology, the time spent in body postures can be recorded. |
The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
|
(Serious) adverse events
Tidsramme: Throughout study period
|
Systematically recording all adverse events |
Throughout study period
|
|
Patient expectations concerning SCS
Tidsramme: Evaluated at baseline visit
|
Self-constructed open question to evaluate patient expectations about SCS |
Evaluated at baseline visit
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- DETECT
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .